SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
Automated parallel capillary electrophoresis system simplifies protein analysis
Demonstrate significant bleed reduction in hemophilia A and B
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Subscribe To Our Newsletter & Stay Updated
